



(51) International Patent Classification:

C07J 3/00 (2006.01) A61K 31/573 (2006.01)
C07J 7/00 (2006.01) A61K 31/58 (2006.01)
C07J 15/00 (2006.01) A61P 25/00 (2006.01)
A61K 31/57 (2006.01)

(21) International Application Number:

PCT/CN2014/075594

(22) International Filing Date:

17 April 2014 (17.04.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2013/074323 17 April 2013 (17.04.2013) CN

(71) Applicant: **SAGE THERAPEUTICS, INC.** [US/US];
215 First Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors; and

(71) Applicants (for US only): **BOTELLA, Gabriel Martinez** [ES/US]; 17 Parmenter Road, Wayland, Massachusetts 01778 (US). **HARRISON, Boyd L.** [US/US]; 9 Wheatston Court, Princeton Junction, New Jersey 08550 (US). **ROBICHAUD, Albert Jean** [US/US]; 3 Riverview Court, Ringoes, New Jersey 08551 (US). **SALITURO, Francesco G.** [US/US]; 25 Baker Drive, Marlborough, Massachusetts 01752 (US). **BERESIS, Richard Thomas** [US/CN]; Apartment 2504, Building 1, 199 Shimen #2 Road, Shanghai 200040 (CN).

(74) Agent: **LIU, SHEN & ASSOCIATES**; A0601, Huibin Building, No.8 Beichen Dong Street, Chaoyang District, Beijing 100101 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF



(57) Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein, R¹, R², R^{3a}, R^{3b}, R^{4a}, R^{4b}, R⁵, R⁶, and R⁷ are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

